eMedicine Specialties > Pediatrics: Genetics and Metabolic Disease > Genetics
von Hippel-Lindau Disease: Follow-up
Updated: Apr 20, 2009
Follow-up
Further Outpatient Care
Because of the pleiotropic clinical manifestations of von Hippel-Lindau (VHL) disease, or von Hippel-Lindau syndrome, and the potential for malignancy, a lifelong strategy of surveillance (particularly for the brain, eyes, and kidneys) is necessary for early detection and treatment of complications. A reasonable annual surveillance strategy for affected patients and at-risk relatives is as follows:
- Obtain laboratory studies annually, starting at age 5 years. Testing consists of urinalysis, urine cytologic examination, urinary catecholamine metabolites, CBC count, and plasma catecholamines.
- Perform annual direct and indirect ophthalmoscopic examinations; this is best if started before age 5 years.
- Perform audiologic examination at the first sign of hearing problems, vertigo, or tinnitus. When abnormalities are found, a T1-weighted MRI of the temporal bone should be performed .
- Some experts recommend that MRI of the brain to properly assess the posterior fossa should be performed every 2-3 years, beginning at age 10-15 years. This recommendation is controversial. Typically, space-occupying lesions in the CNS causes neurological symptoms. If lesions are present and the patient is asymptomatic, they are usually not resected.
- Perform annual abdominal ultrasonography, beginning at age 16 years, to look for abnormalities in the kidneys, adrenal glands and/or pancreas. Concerning findings warrant further investigation with either CT scans or MRI.
- Screening may be discontinued for at-risk relatives at approximately age 60 years, if no abnormalities have been found.
- Genetic testing includes the following:
- Once diagnosed, a search for the causative mutation (in the originally identified patient or "proband") can benefit family members. If the proband's causative mutation can be identified, then its presence or absence in at-risk family members can reliably and unequivocally define their status. Individuals who have not inherited the mutant VHL allele can dispense with the burdensome and expensive task of unnecessary annual screening, and individuals with the mutant allele can be closely monitored for early manifestations.
- Genetic testing for mutations in the VHL gene requires complete sequencing of the coding regions and is approximately 80% sensitive. The addition of Southern blot analysis detects virtually all mutations. In the rare event that no causative mutation is identified in the proband, all at-risk relatives must continue to undergo annual screening at least until age 60 years, as outlined above.
Patient Education
- Genetic testing is performed at several laboratories in the United States, including the following:
- Boston University School of Medicine, Center for Human Genetics, Boston, Massachusetts
- Children's Mercy Hospital, Molecular Genetics Laboratory, Kansas City, Missouri
- Johns Hopkins Hospital, DNA Diagnostic Laboratory, Baltimore, Maryland
- University of Pennsylvania School of Medicine, Genetic Diagnostic Laboratory, Philadelphia, Pennsylvania
- Patients and families can benefit from contacting the VHL Family Alliance at 800-767-4845 (800-767-4VHL) or by email at info@vhl.org. The VHL Family Alliance Web site is www.vhl.org.
- The National Cancer Institute through the US National Institutes of Health sponsors a Web site (www.cancer.gov) with general information that may be useful to patients with VHL syndrome and their families.
- Additional support organizations are:
- Kidney Cancer Association at 800-516-8051 or 847-332-1051. The Web site is www.curekidneycancer.org.
- NIH/National Eye Institute at 301-496-5248. The Web site is www.nei.nih.gov.
Miscellaneous
Medicolegal Pitfalls
- Failure to recognize von Hippel-Lindau (VHL) disease, or von Hippel-Lindau syndrome, results in a risk to the patient because further appropriate screening modalities will not be performed.
- If a patient presents with one manifestation of von Hippel-Lindau disease (eg, retinal hemangioblastoma), treating the manifestation in isolation is not sufficient. The patient is at risk for additional life-threatening problems that may not be immediately obvious. If screening is not initiated for occult manifestations, the physician may be liable when the patient presents with other manifestations (eg, advanced renal cell carcinoma). Surveillance for von Hippel-Lindau disease–associated conditions is considered the standard of care, and failure to implement such measures may result in liability.
- Consider von Hippel-Lindau disease in a patient in whom retinal or cerebellar hemangioblastoma, multiple renal cysts, or a pheochromocytoma is diagnosed.
- Because von Hippel-Lindau disease is inherited, potential liability is reported in another major area. If von Hippel-Lindau disease is diagnosed in a patient, an extensive family history must be obtained and appropriate family members must be screened for von Hippel-Lindau disease. If family members are not notified of the risk and are unaware of the need to undergo regular examinations, substantial morbidity and mortality may result, with obvious legal ramifications.
- For the above reasons, consultation with a geneticist or genetic counselor is strongly recommended when a patient is thought to have von Hippel-Lindau disease.
The authors and editors of eMedicine gratefully acknowledge the contributions of previous authors James P Evans, MD, PhD and Cecile Skrzynia, MS, CGC, to the original writing and development of this article.
More on von Hippel-Lindau Disease |
| Overview: von Hippel-Lindau Disease |
| Differential Diagnoses & Workup: von Hippel-Lindau Disease |
| Treatment & Medication: von Hippel-Lindau Disease |
 Follow-up: von Hippel-Lindau Disease |
| Multimedia: von Hippel-Lindau Disease |
| References |
| « Previous Page | Next Page » |
References
Turturro F. Beyond the Knudson's hypothesis in von Hippel-Lindau (VHL) disease-proposing vitronectin as a "gene modifier". J Mol Med. Apr 8 2009;[Medline].
Krzysztolik K, Cybulski C, Sagan L, Nowacki P, Lubinski J. Endolymphatic sac tumours and von Hippel-Lindau disease - case report, molecular analysis and histopathological characterization. Folia Neuropathol. 2009;47(1):75-80. [Medline].
Boedeker CC, Erlic Z, Richard S, et al. Head and Neck Paragangliomas in Von Hippel-Lindau Disease and Multiple Endocrine Neoplasia Type 2. J Clin Endocrinol Metab. Mar 31 2009;[Medline].
Israel GM, Francis IR, Baumgarten DA, et al. Indeterminate renal mass. Reston, VA: ACR; 2007.
Chan-Smutko G, Plon SE, Iliopoulos O. Clinical features, diagnosis, and management of von Hippel-Lindau disease. UpToDate. Available at www.utdol.com/online/content/topic.do?topicKey=brain_ca/15247. Accessed 01/06/2009.
Decker HJ, Weidt EJ, Brieger J. The von Hippel-Lindau tumor suppressor gene. A rare and intriguing disease opening new insight into basic mechanisms of carcinogenesis. Cancer Genet Cytogenet. Jan 1997;93(1):74-83. [Medline].
Huson SM, Rosser EM. Von Hippel-Lindau disease. In: Rimoin DL, Connor JM, Pyeritz RE, Emery AE, eds. Emery and Rimoin's Principles and Practice of Medical Genetics. 3rd ed. Churchill Livingston; 1996:2290-5.
Johns Hopkins University. #193300. OMIM. Available at http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=193300. Accessed June 3, 2002.
Khan AN, Turnbull I, MacDonald S, Al-Okaili R. Von Hippel-Lindau Syndrome. eMedicine from WebMD. Available at emedicine.medscape.com/article/385704. Accessed January 6, 2009.
Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol. Dec 15 2004;22(24):4991-5004. [Medline].
Lindor NM, Greene MH. The concise handbook of family cancer syndromes. Mayo Familial Cancer Program. J Natl Cancer Inst. Jul 15 1998;90(14):1039-71. [Medline].
Maher ER, Kaelin WG Jr. von Hippel-Lindau disease. Medicine (Baltimore). Nov 1997;76(6):381-91. [Medline].
Richards FM, Webster AR, McMahon R, et al. Molecular genetic analysis of von Hippel-Lindau disease. J Intern Med. Jun 1998;243(6):527-33. [Medline].
Schimke NR, Collins DL, Stolle CA. Von Hippel-Lindau Syndrome. GeneReviews. Available at www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=vhl. Accessed January 6, 2009.
Schimke RN, Collins DL, Stolle CA. von Hippel-Lindau Syndrome. GeneTests GeneClinics. Available at http://www.geneclinics.org. Accessed December 1, 2004.
Schoenfeld AR, Davidowitz EJ, Burk RD. Elongin BC complex prevents degradation of von Hippel-Lindau tumor suppressor gene products. Proc Natl Acad Sci U S A. Jul 18 2000;97(15):8507-12. [Medline]. [Full Text].
Sun X, Kanwar JR, Leung E, Vale M, Krissansen GW. Regression of solid tumors by engineered overexpression of von Hippel-Lindau tumor suppressor protein and antisense hypoxia-inducible factor-1alpha. Gene Ther. Dec 2003;10(25):2081-9. [Medline].
VHL Family Alliance. Available at www.vhl.org/aboutvhlfa/index.php. Accessed January 6, 2009.
Von Hippel-Lindau disease. Wikipedia. Available at en.wikipedia.org/wiki/Von_Hippel-Lindau_disease. Accessed 01/06/2009.
Von Hippel-Lindau syndrome. Genetics Home Reference. Available at ghr.nlm.nih.gov/condition=vonhippellindausyndrome. Accessed January 6, 2009.
Von Hippel-Lindau Syndrome. OMIM. Available at www.ncbi.nlm.nih.gov. Accessed February 20, 2009.
Further Reading
Keywords
von Hippel-Lindau disease, von Hippel-Lindau syndrome, VHL syndrome, VHL, von Hippel-Lindau's disease, Hippel disease, Hippel's disease, Hippel-Lindau disease, VHL gene, chromosome 3, 3p26-p25, VHL proteins, pVHL, Knudson's theory of carcinogenesis, retinocerebral angiomatosis, Lindau disease, Lindau's disease, retinal hemangioblastomas, CNS hemangioblastomas, central nervous system hemangioblastomas, pheochromocytomas, renal cyst, pancreatic cyst, renal carcinoma, renal cancer, renal cell carcinoma, RCC, endolymphatic sac tumors, ELSTs, epididymal papillary cystadenomas, treatment, diagnosis, retinal detachment, macular edema, glaucoma, tinnitus
